

**Independent Auditors' Review Report**

To  
The Board of Directors,  
**Vivanza Biosciences Limited**

We have reviewed the accompanying statement of Consolidated Unaudited Financial results of **Vivanza Biosciences Limited** ("The Parent") and its Subsidiary Company (The Parent and its Subsidiary Collectively referred to as "The Group") for the quarter ended 30<sup>th</sup> June, 2018, ("the statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulation, 2015, as modified by circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This statement which is the responsibility of the Parent's Management and approved by the Board of Directors, has been prepared in accordance with the recognition & measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), Prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan & perform the review to obtain moderate assurance as to whether the statement is free of Material Misstatement. A review is limited primarily to Inquires of the Parent's personnel and analytical procedures applied to the financial data and thus provide less assurance than an audit. We have not performed an Audit and, accordingly, we do not express an Audit opinion.

The statement includes the results of the wholly-owned subsidiary, **Vivanza Lifesciences Private Limited** (The Subsidiary Company)

The consolidated unaudited financial results include the interim financial information of one wholly-owned subsidiary, as certified by the management, which have not been reviewed/audited by their auditors, whose interim financial information reflect





**G M C A & Co.**


Chartered Accountants

total revenue of Rs. 67,404 for the Quarter ended 30<sup>th</sup> June 2018 and total loss after of Rs. 1,13,154 for the Quarter ended 30<sup>th</sup> June 2018, as considered in the consolidated unaudited financial results.

Based on our review conducted as stated above, and except for the possible effects of the matters described in paragraph 4 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as modified by circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, G M C A & CO.  
Chartered Accountants  
FRN: 109850W



  
CA. Mitt S. Patel  
Partner  
Membership No: 163940

Place: Ahmedabad  
Date: 14<sup>th</sup> August, 2018

## VIVANZA BIOSCIENCES LIMITED

(Formerly Known as IVEE INJECTAA LTD )

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.

CIN : L24110GJ1982PLC005057

### STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2018.

(Rs. In Lacs except per share data)


	Particulars	Quarter Ended		Year Ended	
		30/06/2018	31/03/2018	30/06/2017	31/03/2018
		Unaudited	Audited	Unaudited	Audited
1	<b>Income from Operations</b>				
	(a) Revenue from operations	103.32	122.25	264.15	644.03
	(b) Other Income	0.00	0.00	0.11	0.11
	<b>Total Income</b>	<b>103.32</b>	<b>122.25</b>	<b>264.26</b>	<b>644.14</b>
2	<b>Expenses</b>				
	(a) Cost of Materials consumed	0.00	0.00	0.00	0.00
	(b) Purchase of stock-in-trade	55.77	311.34	64.32	600.24
	(c) Increase/Decrease in inventories of FG, WIP and stock-in-trade	23.26	-209.12	162.64	-47.31
	(d) Employee benefits expense	0.52	0.61	11.03	13.73
	(e) Finance Cost	9.31	7.73	8.56	35.62
	(f) Depreciation and amortisation expense	0.00	0.00	0.00	0.00
	(g) Other expenses	4.61	4.51	11.55	18.51
	<b>Total Expenses</b>	<b>93.47</b>	<b>115.06</b>	<b>258.10</b>	<b>620.79</b>
3	<b>Profit/(loss) before exceptional items and tax (1-2)</b>	<b>9.85</b>	<b>7.19</b>	<b>6.16</b>	<b>23.35</b>
4	Exceptional items	0.00	0.00	0.00	0.00
5	<b>Profit/(Loss) before tax (3-4)</b>	<b>9.85</b>	<b>7.19</b>	<b>6.16</b>	<b>23.35</b>
6	<b>Tax Expense</b>				
	(a) Current tax	0.00	2.81	0.00	2.81
	(b) Deferred tax	0.00	0.00	0.00	0.00
	<b>Total Tax Expenses</b>	<b>0.00</b>	<b>2.81</b>	<b>0.00</b>	<b>2.81</b>
7	<b>Profit / (Loss) for the period from continuing operations (5-6)</b>	<b>9.85</b>	<b>4.38</b>	<b>6.16</b>	<b>20.54</b>
8	<b>Profit (Loss) from discontinuing operations</b>	0.00	0.00	0.00	0.00
9	<b>Tax Expense of discontinuing operations</b>	0.00	0.00	0.00	0.00
10	<b>Profit (Loss) from discontinuing operations (after tax)(8-9)</b>	0.00	0.00	0.00	0.00
11	Share of Profit / ( Loss) of associates *	0.00	0.00	0.00	0.00
12	Minority Interest *	0.00	0.00	0.00	0.00
13	<b>Other Comprehensive Income</b>				
	<b>A(I) Items that will not be reclassified to profit or loss</b>	0.00	0.00	0.00	0.00
	<b>(II) Income tax relating to items that will not be reclassified to profit or loss</b>	0.00	0.00	0.00	0.00
	<b>B (I) Items that will be reclassified to profit or loss</b>	0.00	0.00	0.00	0.00
	<b>II) Income tax relating to items that will be reclassified to profit or loss</b>	0.00	0.00	0.00	0.00
	<b>Other Comprehensive income for the period</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
14	<b>Total Comprehensive Income for the period</b>	<b>9.85</b>	<b>4.38</b>	<b>6.16</b>	<b>20.54</b>
15	<b>Total Comprehensive Income attributable to :</b>				
	Share of Profit / ( Loss) of associates *	0.00	0.00	0.00	0.00
	Minority Interest *	0.00	0.00	0.00	0.00
16	Paid-up equity share capital (Face value of Rs.10/- each)	400	400	400	400
17	<b>Earnings Per Share (before extraordinary items) (not annualised):</b>				
	(a) Basic	0.25	0.11	0.15	0.51
	(b) Diluted	0.25	0.11	0.15	0.51
18	<b>Earnings Per Share (after extraordinary items) (not annualised):</b>				
	(a) Basic	0.25	0.11	0.15	0.51
	(b) Diluted	0.25	0.11	0.15	0.51

**Notes:**

1. The above audited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on August, 14, 2018. The Limited Review under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the statutory auditors. The Limited Review Report does not contain any observation which could have an impact on the results for the quarter ended June 30, 2018.

2. The Company adopted the Indian Accounting Standards ('Ind AS') effective 1st April, 2017 (transition date 1st April, 2016). The financial results have been prepared in accordance with Ind AS as prescribed under Section 133 of the Companies Act, 2013 read with the relevant Rules issued there under.

3. The Company operates only in single segment i.e. pharmaceuticals related activities



For, VIVANZA BIOSCIENCES LIMITED

**MANOJ K. BHASKAR BHATTACHARYA**

**MANAGING DIRECTOR**

**DIN : 07487250**

Date : 14/08/2018

Place : Ahmedabad



**GMCA & Co.**

Chartered Accountants

To,  
The Board of Directors,  
**Vivanza Biosciences Limited**  
Ahmedabad

We have reviewed the accompanying statement of Unaudited Financial Results (the statement) of **M/s Vivanza Biosciences Limited** ("the Company") for the first quarter ended 30<sup>th</sup> June, 2018 attached herewith being submitted by company to the stock exchanges viz. BSE pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Discloser Requirements) Regulations, 2015 read with Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016.

The preparation of the statement in accordance with the recognition and measurement principles laid down in the Indian Accountant Standard 34 "Interim Financial Reporting" (IND-AS 34), prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015 & SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016 is the responsibility of the Company's management and has been approved the by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review in accordance with the standard on review engagement (SRE) 2410, Review Financial Information performed Auditor of Entity, issued by the institute of Chartered Accountant of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and accordingly / we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results, prepared in accordance with applicable Indian Accounting standards (Ind AS) prescribed under section 133 of the companies act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies, has not disclosed the information required to be Disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations , 2015 read with SEBI circular





**G M C A & Co.**

Chartered Accountants

number CIR/CFD/FAC/62/2016 Dated 5<sup>th</sup> July 2016 including the manner in which it is to be disclosed or that is contains any material misstatement.

For, G M C A & CO.  
Chartered Accountants  
FRN: 109850W



  
CA. Mitt S. Patel  
Partner

Membership No: 163940

Place: Ahmedabad

Date: 14<sup>th</sup> August, 2018

**VIVANZA BIOSCIENCES LIMITED**

**(Formerly Known as IVEE INJECTAA LTD )**

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.

CIN : L24110GJ1982PLC005057

**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2018.**

**(Rs. in Lacs except per share data)**

Particulars	Quarter Ended		Year Ended	
	30/06/2018	31/03/2018	30/06/2017	31/03/2018
	Unaudited	Audited	Unaudited	Audited
<b>1 Income from Operations</b>				
(a) Revenue from operations	102.64	122.26	264.15	644.03
(b) Other Income	0.00	0.00	0.11	0.11
<b>Total Income</b>	<b>102.64</b>	<b>122.26</b>	<b>264.26</b>	<b>644.14</b>
<b>2 Expenses</b>				
(a) Cost of Materials consumed	0.00	0.00	0.00	0.00
(b) Purchase of stock-in-trade	41.64	311.33	64.32	600.24
(c) Increase/Decrease in inventories of FG, WIP and stock-in-trade	37.24	-209.12	162.64	-47.31
(d) Employee benefits expense	0.00	0.18	9.13	10.42
(e) Finance Cost	9.31	8.74	8.56	35.56
(f) Depreciation and amortisation expense	0.00	0.00	0.00	0.00
(g) Other expenses	3.47	3.37	11.55	18.42
<b>Total Expenses</b>	<b>91.66</b>	<b>114.50</b>	<b>256.20</b>	<b>617.33</b>
<b>3 Profit/(loss) before exceptional items and tax (1-2)</b>	<b>10.98</b>	<b>7.76</b>	<b>8.06</b>	<b>26.81</b>
<b>4 Exceptional Items</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>5 Profit/(Loss) before tax (3-4)</b>	<b>10.98</b>	<b>7.76</b>	<b>8.06</b>	<b>26.81</b>
<b>6 Tax Expense</b>				
(a) Current tax	0.00	2.81	0.00	2.81
(b) Deferred tax	0.00	0.00	0.00	0.00
<b>Total Tax Expenses</b>	<b>0.00</b>	<b>2.81</b>	<b>0.00</b>	<b>2.81</b>
<b>7 Profit / (Loss) for the period from continuing oprations (5-6)</b>	<b>10.98</b>	<b>4.95</b>	<b>8.06</b>	<b>24.00</b>
<b>8 Profit (Loss) from discontinuing oprations</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>9 Tax Expense of discontinuing oprations</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>10 Profit (Loss) from discontinuing oprations (after tax)(8-9)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>11 Other Comprehensive Income</b>				
<b>A(I) Items that will not be reclassified to profit or loss</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>(II) Income tax relating to items that will not be reclassified to profit or loss</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>B (I) Items that will be reclassified to profit or loss</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>ii) Income tax relating to items that will be reclassified to profit or loss</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>Other Comprehensive Income for the period</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>12 Total Comprehensive Income for the period</b>	<b>10.98</b>	<b>4.95</b>	<b>8.06</b>	<b>24.00</b>
<b>13 Paid-up equity share capital (Face value of Rs. 10/- each)</b>	<b>400</b>	<b>400</b>	<b>400</b>	<b>400</b>
<b>14 Earnings Per Share (before extraordinary items) (not annualised):</b>				
(a) Basic	0.27	0.12	0.20	0.60
(b) Diluted	0.27	0.12	0.20	0.60
<b>15 Earnings Per Share (after extraordinary items) (not annualised):</b>				
(a) Basic	0.27	0.12	0.20	0.60
(b) Diluted	0.27	0.12	0.20	0.60


**Notes:**

1. The above standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on August 14, 2018. The Limited Review under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the statutory auditors. The Limited Review Report does not contain any observation which could have an impact on the results for the quarter ended June 30, 2018.

2. The Company adopted the Indian Accounting Standards ('Ind AS') effective 1st April, 2017 (transition date 1st April, 2016). The financial results have been prepared in accordance with Ind AS as prescribed under Section 133 of the Companies Act, 2013 read with the relevant Rules issued there under.

3. The Company operates only in single segment i.e. pharmaceuticals related activities

Date : 14/08/2018  
Place : Ahmedabad

For: VIVANZA BIOSCIENCES LIMITED  
  
BHASKAR BHATTACHARYA  
MANAGING DIRECTOR  
DIN : 07487250